Interpace Biosciences Inc (IDXG)
Interpace Biosciences, Inc. is a healthcare company focused on molecular diagnostic testing, bioinformatics, and pathology services used to assess cancer risk in the United States. Its portfolio includes PancraGEN, a genomic test for pancreatic cysts and pancreaticobiliary solid lesions; PanDNA, a molecular-only version of PancraGEN; ThyGeNEXT, a mutation panel for identifying malignant thyroid nodules; ThyraMIR v2, which evaluates thyroid nodule malignancy risk using a microRNA gene expression classifier; and RespriDx, a genomic test designed to help distinguish metastatic or recurrent lung cancer. The company serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. Founded in 1986 and headquartered in Parsippany, New Jersey, it was previously known as Interpace Diagnostics Group, Inc. before adopting its current name in November 2019.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-IDXG
|
$1.64
|
10.0% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
1.7x
|
1.8x
|
1.1x
|
41.274 M
|
39.707 M
|
2.5%
|
12.5%
|
-4.7
|
—
|
18.2%
|
